Dobrin P B, Golan J, Fareed J, Blakeman B, Littoy F N
Department of Surgery, Loyola University Medical Center, Maywood, Illinois.
J Cardiovasc Surg (Torino). 1992 Nov-Dec;33(6):705-9.
Several clinical studies have shown that pharmacologic inhibition of platelets can increase the patency of vascular grafts, but only if platelet-inhibition is initiated before surgery. This study was performed to compare the efficacy of pre- vs postoperative platelet-inhibition on the development of intimal hyperplasia in canine autogenous vein grafts. Reversed femoral veins were used to bypass the ligated femoral arteries in 15 dogs. End-to-side anastomoses were constructed. Eleven dogs were treated with aspirin (325 mg QD) and dipyridamole (25 mg BID). In six dogs treatment was begun 48 hours preoperatively and continued for 3 months. In five other dogs treatment was begun 48 hours after surgery and was continued for 3 months. In 4 control dogs no antiplatelet treatment was given. Excision of the vein grafts 3 months after surgery disclosed reduced intimal hyperplasia (p < 0.05) in the grafts excised from all of the treated animals as compared with those obtained from the control animals. However, there was no difference in intimal hyperplasia observed in the dogs treated both pre- and postoperatively (11 grafts) as compared with those treated only postoperatively (9 grafts). These data demonstrate that it is not necessary to begin antiplatelet therapy preoperatively in order to inhibit intimal hyperplasia. They also suggest that preoperative antiplatelet therapy may improve early graft patency by directly preventing thrombosis, not by inhibiting the development of intimal hyperplasia.
多项临床研究表明,对血小板进行药物抑制可提高血管移植物的通畅率,但前提是在手术前开始抑制血小板。本研究旨在比较术前与术后抑制血小板对犬自体静脉移植物内膜增生发展的疗效。使用15只犬的股静脉反转来绕过结扎的股动脉,构建端侧吻合。11只犬接受阿司匹林(325mg,每日一次)和双嘧达莫(25mg,每日两次)治疗。6只犬在术前48小时开始治疗并持续3个月。另外5只犬在术后48小时开始治疗并持续3个月。4只对照犬未接受抗血小板治疗。术后3个月切除静脉移植物发现,与对照犬的移植物相比,所有接受治疗动物的移植物内膜增生均减少(p<0.05)。然而,术前和术后均接受治疗的犬(11个移植物)与仅术后接受治疗的犬(9个移植物)在内膜增生方面没有差异。这些数据表明,为抑制内膜增生,不必在术前开始抗血小板治疗。它们还表明,术前抗血小板治疗可能通过直接预防血栓形成而非抑制内膜增生的发展来改善早期移植物通畅率。